Ibio Pharma Inc

NEW YORK, Aug. (NYSE AMERICAN:IBIO) today announced that it has entered into a collaboration with EdgePoint AI, a division of Mateon Therapeutics, Inc. : 262797813 | State of Incorp. (AMEX:IBIO). for the development of Planet's COVID-19 therapeutic candidate, ACE2-Fc. INOVIO’s first-of-their-kind DNA medicines are precisely designed DNA plasmids delivered through INOVIO’s proprietary smart device — CELLECTRA ® — directly into the body’s cells to produce an immune response robust enough to potentially treat or prevent disease. (), to deploy EdgePoint’s proprietary artificial intelligence (“AI”)/blockchain-driven vision system for pharmaceutical manufacturing, known as TrustPoint Fabric. NYSEAMERICAN:IBIO gained 4. Thinking about buying stock in Zomedica Pharmaceuticals, iBio Inc, Achieve Life Sciences, Intec Pharma, or Apple Inc? NEW YORK , July 22, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ZOM, IBIO, ACHV, NTEC, and AAPL. It also remains very technical as with all other stocks. Focused initially on clients with preclinical and clinical stage programs, iBio’s fill-finish operation is housed in the Company’s 135,000 square foot CDMO facility. Time is, unfortunately, not on iBio’s side as the race for the vaccine is already progressing at a rapid pace. (NYSE:IBIO) ("iBio" or the "Company"), a biotechnology corporation and biologics contract manufacturing organization, today provided an update on one of its proprietary vaccine candidates being designed to prevent infection from the SARS-CoV-2 virus. In late February shares of iBio Inc. settled a putative securities class action in Delaware federal court Thursday, agreeing to pay roughly $1. 13)* iBio, Inc. Iscriviti per ricevere promozioni esclusive. Idera Pharma secures $20M capital raise. He also held the position of CEO of H Lundbeck A/S, a pharmaceutical company specialized in psychiatric and neurological disorders, for several years. 87 M) of positive cash flow from operations. Price Gain: 794. IBio Inc currently holds about 10. settled a putative securities class action in Delaware federal court Thursday, agreeing to pay roughly $1. 07% so far today. Correvio Pharma Corp | 621 followers on LinkedIn | Correvio Pharma Corp. iBio is an innovator biologics company developing therapeutics and vaccines for the betterment of human and animal health with pipeline candidates targeting systemic sceleroderma (IBIO-100), COVID-19 (IBIO-200 and IBIO-201), and classical swine fever (IBIO-400). NEW YORK, Dec. Usually, stocks from similar sector tend to move together but companies that have innovative products, services or good management tend to outperform. quote is equal to 1. Press Release Thinking about buying stock in Zomedica Pharmaceuticals, iBio Inc, Achieve Life Sciences, Intec Pharma, or Apple Inc? Published: July 22, 2020 at 10:35 a. Its FastPharming System™ combines vertical farming, automated hydroponics, and glycan engineering technologies to rapidly deliver gram quantities of high-quality monoclonal antibodies, vaccines, bioinks and other proteins. Solutions; Quotes. Many companies, which are working on COVID 19 vaccines have seen their stocks skyrocket, and one such company is Ibio Inc (NYSEAMERICAN:IBIO). We’ve been through 6 bear markets (since 1973), waddled through sector mania’s in Biotech, Solar, Patent Monetization, Dotcom, Bitcoin, and Marijuana and we’ve never seen anything like this. 3) Trillium Therapeutics Inc. iBio, a leader in developing plant-based biopharmaceuticals, provides a range of product and process development, analytical, and manufacturing services at the large-scale development and manufacturing facility of its subsidiary iBio CDMO, LLC in Bryan, Texas. for the development of Planet's COVID-19 therapeutic candidate, ACE2-Fc. Thinking about buying stock in Zomedica Pharmaceuticals, iBio Inc, Achieve Life Sciences, Intec Pharma, or Apple Inc? /* Style Definitions */ span. 04 million in revenue during the last quarter. Environment 43 Employees 50 Community 43 Governance 56. 0 thousand shares of iBio Inc. Kitov Pharma | 513 followers on LinkedIn | We are a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, to create successful long-lasting treatments for people with cancer. Why iBio Stock Will Keep Struggling. 3 weeks IBIO Stock Price: iBioPharma Inc to attract Robinhood bargain-seekers amid doubtful Russia’s vaccine FXStreet. Time is, unfortunately, not on iBio’s side as the race for the vaccine is already progressing at a rapid pace. SG AMERICAS SECURITIES LLC bought a fresh place in iBio Inc. By Adam Feuerstein. This is #COCP IS GOING to fly like #Ibio and #HTBX IT IS THE LAST OF THE covd stocks that has not moved it ready to Skyrocket on any news 回覆 回覆數 (2). Ibio Inc (NYSEMKT:IBIO) closed at $1. Share your opinion and gain insight from other stock traders and investors. Our records show it was established in 2008 and incorporated in Delaware. You are hereby notified that Levi & Korsinsky, LLP has commenced an. The statement about iBio collecting pre-clinical data on IBIO-201 wouldn’t be bad news under normal circumstances, but the fight against Covid-19 isn’t normal. The Wall Street of Stock Trading and Investing Financial Community Site for Traders and Investors. Antares Pharma Inc. Reddit gives you the best of the internet in one place. Zealand Pharma A/S (ZEAL) and iBio Inc. "iBio Inc is a part of the healthcare sector. iBio, a biologics contract manufacturing organization and biotechnology company, announced in a March 26, 2020 press release that it has entered into a second statement of work under its master joint development agreement (MJDA) with AzarGen Biotechnologies, which was signed in 2018. recently announced the commencement of a strategic commercial relationship with CC-Pharming Ltd. company page in New York , NY. 07% on Tuesday amidst FDA backtracking on plasma treatments for COVID-19. About Categorized under Pharmaceutical Preparations. Market capitalization usually refers to the total value of a company's stock within the entire market. NYSEAMERICAN:IBIO gained 4. iBio Pharma (NYSEMKT:IBIO) began the year a lot smaller than Arcturus with its market cap standing below $14 million. 47% on its previous day’s price. IBIO / iBio Inc. quote is equal to 1. Lets take a look at what they do as a company: "iBio is an innovator biologics company developing therapeutics and vaccines […]. Recro Pharma, Inc. More From InvestorPlace 2 Toxic Pot Stocks You Should Avoid 10. iBioPharma Inc is working on a plant-based COVID-19 vaccine with Beijing CC-Pharming Ltd. , a biotechnology company, provides product development and manufacturing services to clients, collaborators, and third-party customers in the United States and internationally. The blue-chip FTSE 100was down 0. NEW YORK, June 26, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. Antares Pharma Inc. and iBio CDMO business segments. 23, 2019 (GLOBE NEWSWIRE) -- iBio, Inc. NEW YORK, June 24, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. , is a global leader in plant-based biologics manufacturing. iBio Pharma (NYSEMKT:IBIO) and Vaxart (NASDAQ:VXRT) rank as two of the biggest winners so far this year among small-cap biotechs with coronavirus programs. by granting it an exclusive, royalty-bearing commercial license to iBio's bio-better rituximab ("iBio Rituximab. According to WSJ, iBio Inc. Why iBio Stock Will Keep Struggling. ’s current insider ownership accounts for 5. Trademark registration by iBio, Inc for the trademark FASTPHARMING. Ibio Inc (NYSEMKT:IBIO) closed at $1. iBio, a biologics contract manufacturing organization and biotechnology company, announced in a March 26, 2020 press release that it has entered into a second statement of work under its master joint development agreement (MJDA) with AzarGen Biotechnologies, which was signed in 2018. • List of IBIO Customers. iBio is developing proprietary products for the treatment of a range of fibrotic diseases including idiopathic pulmonary fibrosis, systemic sclerosis, and scleroderma. The Wall Street of Stock Trading and Investing Financial Community Site for Traders and Investors. Combining two strong trends may trigger further gains toward a $1 billion valuation. , the website is managed by Revelers. Heads Equals Royalties, Tails Equals Cash: Trip. 06% so far today. 83% 2020 year-to-date; Market Capitalization: $877. 04 million in revenue during the last quarter. According to WSJ, iBio Inc. The iBio/CC-Pharming partnership is currently in the conceptual design stage with a timeline that iBio calls “aggressive but reasonable. develops pharmaceutical product applications using its iBio Technology platform; a platform that has proven to be more efficient and cost-effective than traditional systems. 52, while invested capital returns managed to touch -51. 's (IBIO) annual meeting of stockholders is all set to be held on March 5, 2020, at 9:30 a. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”) today announced the activation of its new cGMP sterile fill-finish services operation via the signing of a supply agreement with a clinical-stage biopharmaceutical company developing breakthrough gene and cell therapies (the “Customer”). Find contact's direct phone number, email address, work history, and more. () Stock Market info Recommendations: Buy or sell iBio, Inc. iBio, a leader in developing plant-based biopharmaceuticals, provides a range of product and process development, analytical, and manufacturing services at the large-scale development and manufacturing facility of its subsidiary iBio CDMO, LLC. While iBio Pharma typically focuses on vaccines from plant proteins, it has used its research in the past for human plasma treatments, reports The Motley Fool. Exchange / Ticker NYSE American: IBIO Offering Size Up to $15M (100% Secondary) Over Allotment 15% (100% Secondary) Offering Details Common Stock, Preferred Stock and Warrants Use of Proceeds We intend to use the net proceeds from this offering for working capital and general corporate purposes Sole Book - Runner A. Report Highlights: • The Angioedema Treatment report provides a detailed analysis of current and future Angioedema Treatment market trends to identify investment. Why iBio Stock Will Keep Struggling. 23, 2019 (GLOBE NEWSWIRE) -- iBio, Inc. Isett lll, also known as Tom, has been a Director at iBio, Inc. Holtz is the principal of Holtz Biopharma Consulting, a member of the Klyo Collaborative. iBio is a company with a long-term vision and growth strategy. iBIO is a life sciences industry association that represents the 85,000 life sciences employees at member companies, universities, service providers and venture firms. Its FastPharming System™ combines vertical farming, automated hydroponics, and glycan engineering technologies to rapidly deliver gram quantities of high-quality monoclonal antibodies, vaccines, bioinks and other proteins. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”), a biotechnology corporation and biologics contract manufacturing organization, today provided an update on one of its proprietary vaccine candidates being designed to prevent. (IBIO) is up more than 35% at $5. for the development of Planet's COVID-19 therapeutic candidate, ACE2-Fc. 4% fall for car dealer Inchcapeas it said it also posted a pretax loss in the first half of the year. iBio is a global leader in plant-based biopharmaceutical contract development and cGMP manufacturing services. NYSEAMERICAN: IBIO is benefiting from impressive performance amid an ever-crowding field of pharma firms racing. The iBioLaunch platform is a proprietary, transformative technology for the production of biologics including monoclonal antibodies and other therapeutic proteins and vaccines. But after its shares racked up gains of more than 1,700%, iBio. According to WSJ, iBio Inc. Meanwhile, IBIO-201 and IBIO-200 are still at the pre-clinical stage. iBio is a contract development and manufacturing organization equipped to take clients from the early stages of product selection through regulatory. 31 points for debt to equity in total, while total debt to capital is set at the value of 90. 39 and 5Y monthly beta was reading -5. tradingview. The statement about iBio collecting pre-clinical data on IBIO-201 wouldn’t be bad news under normal circumstances, but the fight against Covid-19 isn’t normal. , is a global leader in plant-based biologics manufacturing. Earlier in June, iBio introduced its new cGMP sterile fill-finish capabilities for pharmaceutical products, including monoclonal antibodies, viral vectors and other biologics. Its FastPharming System™ combines vertical farming, automated hydroponics, and glycan engineering technologies to rapidly deliver gram quantities of high-quality monoclonal antibodies, vaccines, bioinks and other proteins. The company uses tobacco-related plants and a process called FastPharming. The micro-cap biotech company remains a penny-stock darling despite having only a longshot for. develops pharmaceutical product applications using its iBio Technology platform; a platform that has proven to be more efficient and cost-effective than traditional systems. IBio Inc has a poor financial position based on the latest SEC disclosures: Latest headline from investorplace. Free stock quotes, news, research, message postings, stock picks, chat rooms, and financial content. The statement about iBio collecting pre-clinical data on IBIO-201 wouldn’t be bad news under normal circumstances, but the fight against Covid-19 isn’t normal. IBio is now headquartered in New York City. Total capital return value is set at -45. Its lead produc t candidate is OC-01 (varenicline), a. For example, a 1000 share position pre-split, became a 100 share position following the split. Taking a more long-term approach, IBIO posted a 52-week range of $0. gains, shrugging off pullback for biotech plasma players FXStreet. Price Gain: 905. It operates through the iBio, Inc. The split for IBIO took place on June 11, 2018. iBioPharma Inc is working on a plant-based COVID-19 vaccine with Beijing CC-Pharming Ltd. He holds a CPA license in New York State. The company says it has completed about ten preclinical arms of study for the antigen-adjuvant combinations. At Walletinvestor. In another most recent transaction, which held on 6/30/2020, WEDBUSH SECURITIES, INC. The collaboration will use iBio's FastPharming system, which was established in 2010 with funding from the U. The split for IBIO took place on June 11, 2018. Corrected IBio's stock rockets on heavy volume after Russell index inclusion Shares of iBio Inc. **All posts on this blog are information and opinions only. New York’s iBio has inked a deal with CC-Pharming of Beijing, for the joint development of products and manufacturing facilities for the Chinese biopharmaceutical market. From drug development to manufacturing, we cover the latest developments, views and opinions from industry leaders in print and online. in Bryan, Texas. iBio is developing proprietary products for the treatment of a range of fibrotic diseases including idiopathic pulmonary fibrosis, systemic sclerosis, and scleroderma. It also remains very technical as with all other stocks. New York, New York--(Newsfile Corp. Wize Pharma Ltd. Meanwhile, IBIO-201 and IBIO-200 are still at the pre-clinical stage. IBio is now headquartered in New York City. The Company has two vaccine candidates for COVID-19, under preclinical development. Recro Pharma, Inc. M2 PHARMA-November 22, 2016-iBio awarded another patent for plague vaccine (C)2016 M2 COMMUNICATIONS Biotechnology company iBio (NYSE MKT:IBIO) reported on Monday the receipt of the new Canadian plague patent under its iBioModulator thermostable immunomodulator protein portfolio. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”) today announced the activation of its new cGMP sterile fill-finish services operation via the signing of a supply agreement with a clinical-stage biopharmaceutical company developing breakthrough gene and cell therapies (the “Customer”). Earlier in June, iBio introduced its new cGMP sterile fill-finish capabilities for pharmaceutical products, including monoclonal antibodies, viral vectors and other biologics. Thinking about buying stock in Zomedica Pharmaceuticals, iBio Inc, Achieve Life Sciences, Intec Pharma, or Apple Inc? Provided by PR Newswire Jul 22, 2020 2:35 PM UTC Sponsor Center. New York-based iBio Inc. (NYSEAMERICAN:IBIO) Comparing side by side 01:06am, Sunday, 17'th Mar 2019 Both Zealand Pharma A/S (NASDAQ:ZEAL) and iBio Inc. IBio Inc Dr. IBIO Description — iBio Inc iBio and subsidiaries is a plant-based expression biologics contract development and manufacturing organizations equipped to deliver pre-clinical development through regulatory approval, commercial product launch and on-going commercial phase requirements. Our belief is that. com/Path_Trading Visit. 30 in pre-market trading today on no news. 91, as the Stock market unbolted on July 17, 2020. , a biotechnology innovator and biologics contract manufacturing organization, has entered into an exclusive worldwide license agreement with Planet Biotechnology Inc. Share your opinion and gain insight from other stock traders and investors. , incorporated on April 17, 2008, is a biotechnology company. iBio Pharma (NYSEMKT:IBIO) began the year a lot smaller than Arcturus with its market cap standing below $14 million. , the website is managed by Revelers. IO Media Group Inc. 0 equity research analysts rated the shares with a selling strategy, 0 gave a hold approach, 1 gave a purchase tip, 0 gave the firm a overweight advice and 0 put the stock under the underweight category. 06% so far today. , a biotechnology innovator and biologics contract manufacturing organization, has entered into an exclusive worldwide license agreement with Planet Biotechnology Inc. 78 % year on year, sequentially revnue fell by -69. Why iBio Stock Will Keep Struggling. iBio is a global leader in plant-based biologics manufacturing. With a commercial presence and distribution network covering over 60 countries worldwide, Correvio develops, acquires and commercializes brands for the. 's (IBIO) annual meeting of stockholders is all set to be held on March 5, 2020, at 9:30 a. Meanwhile, IBIO-201 and IBIO-200 are still at the pre-clinical stage. Wize Pharma is focused on the treatment of ophthalmic disorders, including Dry Eye Syndrome and other inflammatory conditions. , formerly known as iBioPharma Inc. Scopri le migliori offerte per Marche | Openfarma. Ulf is a non-executive member of the board of Alfa Laval AB, Agenus Inc and at the Belgian pharmaceutical company UCB. Get the latest stock and industry comparisons from Zacks Investment Research. 23, 2019 (GLOBE NEWSWIRE) -- iBio, Inc. The Company is focused on commercializing its technologies and product candidates and providing product development and manufacturing services to clients and. ("iBio" or the "Company" (NYSE:IBIO) common stock during the period between October 13, 2014 and October. 2% on Tuesday after the Bryan, Texas-based pharma firm published disappointing earnings figures. Steve Sabus. Meanwhile you can send your letters to 4250 Alafaya Trail, Ste 212-146, Oviedo, FL, 32765. settled a putative securities class action in Delaware federal court Thursday, agreeing to pay roughly $1. Corrected IBio's stock rockets on heavy volume after Russell index inclusion Shares of iBio Inc. iBioPharma Inc is working on a plant-based COVID-19 vaccine with Beijing CC-Pharming Ltd. NEW YORK, Aug. Ibio Inc's share price collapsed by 25. (13)iBio CDMO, LLC, 8800 Health Science Center. Combining two strong trends may trigger further gains toward a $1 billion valuation. The next entry in the theme of Corona Virus stocks is iBioPharma Inc. , the website is managed by Revelers. - A new stake in Ibio Pharma was started on Monday. Time is, unfortunately, not on iBio’s side as the race for the vaccine is already progressing at a rapid pace. Why iBio Stock Will Keep Struggling. Appoints Biotech Trailblazers Brent Saunders and Randy Scott and Renowned Economist Andrew Lo to Board of Directors Email Print Friendly Share June 24, 2020 07:30 ET. The Company is focused on commercializing its technologies and product candidates and providing product development and manufacturing services to clients and. Content is provided by Institutional Analyst Inc. , a biotechnology company, provides product development and manufacturing services to clients, collaborators, and third-party customers in the United States and internationally. CDMO Facility. com: iBio Pharma News Why IBIO Stock Is Surging 25 percent Today - Investorplace. 87 million and attorneys’ fees for allegedly. Meanwhile you can send your letters to 4250 Alafaya Trail, Ste 212-146, Oviedo, FL, 32765. com/Path_Trading Visit. NYSEAMERICAN:IBIO gained 4. About iBio, Inc. Share your opinion and gain insight from other stock traders and investors. 9 thousand shares of the stock in a transaction took place on 6/30/2020. Exchange / Ticker NYSE American: IBIO Offering Size Up to $15M (100% Secondary) Over Allotment 15% (100% Secondary) Offering Details Common Stock, Preferred Stock and Warrants Use of Proceeds We intend to use the net proceeds from this offering for working capital and general corporate purposes Sole Book - Runner A. (NYSE:IBIO) ("iBio" or the "Company"), a biotechnology corporation and biologics contract manufacturing organization, today provided an update on one of its proprietary vaccine candidates being designed to prevent infection from the SARS-CoV-2 virus. Bringing together leaders in the field to utilize over three decades of p53 biology, PMV Pharma combines unique biological understanding with pharmaceutical development focus. 9% after swinging to a rare pretax loss in the first half of 2020 due to higher-than-expected loan loss provisions. (NYSEAMERICAN:IBIO) are Biotechnology companies, competing one another. Antares Pharma Inc. #ibio #stocks #iBioPharma ** TradingView - https://www. - August 24, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities who purchased Cancer Genetics, Inc. IBIO: iBio Inc industry comparisons. , formerly known as iBioPharma Inc. The micro-cap biotech company remains a penny-stock darling despite having only a longshot for. Why iBio Stock Will Keep Struggling. The Company is focused on the discovery, development and commercialization of pharmaceutical therapies to treat ocular surface diseases. (NYSE:IBIO) traded at $2. • List of IBIO Customers. (IBIO) SEC Filing 10-K Annual report for the fiscal year ending Sunday, June 30, 2019. (AIKI) Ownership Facts and Figures. Apple : Thinking about buying stock in Zomedica Pharmaceuticals, iBio Inc, Achieve Life Sciences, Intec Pharma, or Apple Inc?. is a biotechnology company. iBio is a contract development and manufacturing organization equipped to take clients from the early stages of product selection through regulatory. 6500 on the day. Share your opinion and gain insight from other stock traders and investors. Idera Pharma secures $20M capital raise. Thinking about buying stock in Zomedica Pharmaceuticals, iBio Inc, Achieve Life Sciences, Intec Pharma, or Apple Inc? Provided by PR Newswire Jul 22, 2020 2:35 PM UTC Sponsor Center. In another most recent transaction, which held on 6/30/2020, WEDBUSH SECURITIES, INC. Find real-time IBIO - Ibio Inc stock quotes, company profile, news and forecasts from CNN Business. Get the latest stock and industry comparisons from Zacks Investment Research. Investment analysts at H. for the development of Planet's COVID-19 therapeutic candidate, ACE2-Fc. It also remains very technical as with all other stocks. Stock Downgraded (ATRS) By Kevin Baker. stands at -871. Time is, unfortunately, not on iBio’s side as the race for the vaccine is already progressing at a rapid pace. 39 and 5Y monthly beta was reading -5. Taking a look at stock we notice that its last check on previous day was $4. About iBio, Inc. Its FastPharming System™ combines vertical farming, automated hydroponics,. 90% institutional ownership. Wainwright published a research note on March 05, 2019 where it informed investors and clients that Evoke Pharma Inc. The Wall Street of Stock Trading and Investing Financial Community Site for Traders and Investors. The iBio Technology platform is a proprietary gene expression technology that causes non-transgenic plants to rapidly produce high levels of target proteins and has been validated across a wide range of applications in both vaccines and. Cocrystal Pharma, Inc. iBio is a company with a long-term vision and growth strategy. (IBIO) latest news, insider trading and hedge fund ownership data provided by Insider Monkey. 2% on Tuesday after the Bryan, Texas-based pharma firm published disappointing earnings figures. , a biotechnology innovator and biologics contract manufacturing organization, has entered into an exclusive worldwide license agreement with Planet Biotechnology Inc. Long and Short Trading Ideas using Insider Transaction Data. The blue-chip FTSE 100was down 0. Integrated BioPharma (Ticker Symbol: INBP. Thinking about buying stock in Zomedica Pharmaceuticals, iBio Inc, Achieve Life Sciences, Intec Pharma, or Apple Inc? Provided by PR Newswire Jul 22, 2020 2:35 PM UTC Sponsor Center. Related Insiders. WhatsApp iBio, Inc. 30 in pre-market trading today on no news. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”) today introduced new cGMP sterile fill-finish capabilities for pharmaceutical products, including monoclonal antibodies, viral vectors, and other biologics. iBio Inc (NYSEAMERICAN: IBIO) is having a rough start to the trading session this morning, following up on the declines that we saw in the stock yesterday. Horizon Therapeutics, Astellas Pharma US and Baxter International Inc. 19% from its closing price on previous day. 23, 2019 (GLOBE NEWSWIRE) -- iBio, Inc. ”157 Sections 1. IBIO Description — iBio Inc iBio and subsidiaries is a plant-based expression biologics contract development and manufacturing organizations equipped to deliver pre-clinical development through regulatory approval, commercial product launch and on-going commercial phase requirements. Environment 43 Employees 50 Community 43 Governance 56. , Inovio Pharmaceuticals, Janssen Pharmaceutical, Novavax, Sanofi Pasteur, Codagenix, Vaxart Inc and more – all the biggest companies operating in the Global Coronavirus (COVID 19) Vaccine market have been profiled and analyzed in the report as well. rocketed 64% on heavy volume in premarket trading Friday, as the biotherapeutics and contract. announced the formation of a venture to develop and manufacture plant-made pharmaceuticals at a site in Texas. Thinking about buying stock in Zomedica Pharmaceuticals, iBio Inc, Achieve Life Sciences, Intec Pharma, or Apple Inc? NEW YORK , July 22, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ZOM, IBIO, ACHV, NTEC, and AAPL. Ibio Inc's share price collapsed by 25. PSN noted this development and looked for the reason, which resulted in interesting findings. Heads Equals Royalties, Tails Equals Cash: Trip. Find the latest iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”) today introduced new cGMP sterile fill-finish capabilities for pharmaceutical products, including monoclonal antibodies, viral vectors, and other biologics. iBio and Planet Biotechnology Enter into Exclusive Worldwide License Agreement for the Development of a COVID-19 Therapeutic (Ref: GlobeNewswire) Published: 3 days ago. com Group Limited (TCOM), iBio,. iBio Inc iBio, Inc. Meanwhile, IBIO-201 and IBIO-200 are still at the pre-clinical stage. Several Provisional Patents Filed with USPTO NEW YORK, March 18, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) today announced that it has expanded the scope of its business venture with CC-Pharming Ltd. Its FastPharming System™ combines vertical farming, automated hydroponics, and glycan engineering technologies to rapidly deliver gram quantities of high-quality monoclonal antibodies, vaccines, bioinks and other proteins. The valuable technology was developed by Fraunhofer CMB for iBio Inc. iBio Inc CKPT Checkpoint Therapeutics Inc CVM CEL-SCI Corp. The statement about iBio collecting pre-clinical data on IBIO-201 wouldn’t be bad news under normal circumstances, but the fight against Covid-19 isn’t normal. However, we believe new highs are coming after putting all the pieces together. Currencies (Forex) · Stocks. | 4,006 followers on LinkedIn | Speeding time-to-clinic with CDMO Services based on the FastPharming System. 7599 e laureata in Farmacia presso l'università degli studi di Napoli Federico II. BridgeBio Pharma, Inc. The split for IBIO took place on June 11, 2018. Companies, scientists, and researchers have come together to seek a possible vaccine for the pandemic. Why iBio Stock Will Keep Struggling. , formerly known as iBioPharma Inc. Time is, unfortunately, not on iBio’s side as the race for the vaccine is already progressing at a rapid pace. IBio Inc (IBIO) is traded on NYSEMKT Exchange in USA. Mullaney served in the capacity as Corporate Controller for Citihub Consulting, a multi-national IT services firm. The Wall Street of Stock Trading and Investing Financial Community Site for Traders and Investors. iBio and Planet Biotechnology Enter into Exclusive Worldwide License Agreement for the Development of a COVID-19 Therapeutic (Ref: GlobeNewswire) Published: 3 days ago. Majority-owned by a non-profit research foundation, Lundbeck occupies a unique position in Illinois’ life science community. announced the formation of a venture to develop and manufacture plant-made pharmaceuticals at a site in Texas. More From InvestorPlace 2 Toxic Pot Stocks You Should Avoid 10. 2 mins iBio Stock Forecast: iBioPharma Inc. While IBIO stock delivered big gains and ran to $7, it has since dropped back down. The valuable technology was developed by Fraunhofer CMB for iBio Inc. (IBIO) Misled Shareholders According to a Recently Filed Class Action GlobeNewswire - Wed Oct 29, 5:27PM CDT Shareholder rights law firm Robbins Arroyo LLP announces that an investor of iBio, Inc. Looking at the stock we see that its previous close was $1. Detailed company description & address for iBio Inc. More specifically, the company uses the platform to create biologics such as vaccines and. 10, 2020 (GLOBE NEWSWIRE) — iBio, Inc. Investment analysts at H. It also remains very technical as with all other stocks. Major Factors To Watch The IBIO stock has rocketed by as much as 447% this year so far up until June 2, and as the number of coronavirus fatalities went past 100,000, the need for a vaccine is more acute. 07/15 08:37. >> Fraunhofer USA Center for Molecular Biotechnology >>. The mid-cap FTSE 250slipped 0. 600 Madison Avenue Suite 1601 New York, NY 10022. for the development of Planet's COVID-19 therapeutic candidate, ACE2-Fc. Combining two strong trends may trigger further gains toward a $1 billion valuation. NYSEAMERICAN:IBIO gained 4. Find out what works well at Tedor Pharma Inc from the people who know best. Year to date iBio Pharma (NYSEAMERICAN: IBIO) stock is up over 500%. It also remains very technical as with all other stocks. Ibio Inc (NYSEMKT:IBIO) closed at $1. Taking a look at stock we notice that its last check on previous day was $4. According to WSJ, iBio Inc. Lets take a look at what they do as a company: “iBio is an innovator biologics company developing therapeutics and vaccines […]. 23, 2019 (GLOBE NEWSWIRE) -- iBio, Inc. “iBio’s capabilities will enhance our ability to rapidly scale-up vaccine candidate production in an effort to combat the 2019-nCoV virus’ threat to global health. , its former neighbor in the Delaware Technology Park. Holtz is the principal of Holtz Biopharma Consulting, a member of the Klyo Collaborative. Meanwhile, IBIO-201 and IBIO-200 are still at the pre-clinical stage. Find real-time IBIO - Ibio Inc stock quotes, company profile, news and forecasts from CNN Business. The company uses tobacco-related plants and a process called FastPharming. Taking a more long-term approach, IBIO posted a 52-week range of $0. 07/15 08:37. 600 Madison Avenue Suite 1601 New York, NY 10022. IBio Inc Dr. , is a global leader in plant-based biologics manufacturing. 3Rd Francis Thomas Isett, Ceo And. In early February, the company announced a partnership with China-based CC-Pharming to develop a vaccine for the coronavirus. Apple : Thinking about buying stock in Zomedica Pharmaceuticals, iBio Inc, Achieve Life Sciences, Intec Pharma, or Apple Inc?. Time is, unfortunately, not on iBio’s side as the race for the vaccine is already progressing at a rapid pace. IBio Inc currently holds about 10. Earlier in June, iBio introduced its new cGMP sterile fill-finish capabilities for pharmaceutical products, including monoclonal antibodies, viral vectors and other biologics. - Licenses to iBio's Bio-Better Rituximab and FastPharming™ System Expand Commercial Partnership - NEW YORK, Aug. com/gopro/?share_your_love=spekul8r ** Twitter - http://www. iBIO promotes the industry's value to the public and policymakers; connects innovators to investment and talent; stimulates collaboration and fosters the next generation of innovators and entrepreneurs to transform patient. is headquartered in New York, New York. NEW YORK, Dec. iBio, a leader in developing plant-based biopharmaceuticals, provides a range of product and process development, analytical, and manufacturing services at the large-scale development and manufacturing facility of its subsidiary iBio CDMO, LLC. 4% fall for car dealer Inchcapeas it said it also posted a pretax loss in the first half of the year. stands at -871. M2 PHARMA-November 22, 2016-iBio awarded another patent for plague vaccine (C)2016 M2 COMMUNICATIONS Biotechnology company iBio (NYSE MKT:IBIO) reported on Monday the receipt of the new Canadian plague patent under its iBioModulator thermostable immunomodulator protein portfolio. (IBIO) SPO - NASDAQ. 87 million and attorneys’ fees for allegedly. Meanwhile, IBIO-201 and IBIO-200 are still at the pre-clinical stage. 07% on Tuesday amidst FDA backtracking on plasma treatments for COVID-19. The iBio/CC-Pharming partnership is currently in the conceptual design stage with a timeline that iBio calls “aggressive but reasonable. Quotes & Research Flash Quotes InfoQuotes Summary Quotes Real-time Quotes Extended Trading. (Filer) CIK: 0001420720 (see all company filings) IRS No. Ulf is a non-executive member of the board of Alfa Laval AB, Agenus Inc and at the Belgian pharmaceutical company UCB. Find the latest iBio, Inc. 4%, with Lloyds Banking Groupsliding 5. Investment analysts at H. ”157 Sections 1. The micro-cap biotech company remains a penny-stock darling despite having only a longshot for. Corporate social responsibility (CSR) and sustainability data for Ibio Inc, Biotechnology and USA. Why iBio Stock Will Keep Struggling. The Company focuses on developing plant-based biologics manufacturing. The statement about iBio collecting pre-clinical data on IBIO-201 wouldn’t be bad news under normal circumstances, but the fight against Covid-19 isn’t normal. Hedge fund activity in MEI Pharma Inc (NASDAQ:MEIP) At Q3’s end, a total of 6 of the hedge funds tracked by Insider Monkey held long positions in this stock, a gain of 100% from one quarter earlier. iBio CDMO, LLC 8800 HSC Pkwy Bryan, TX 77807. ("Cancer Genetics" or the "Company") (NASDAQ: CGIX) stock prior to August 24, 2020. Breakout Stocks Corona Virus Stocks. Many companies, which are working on COVID 19 vaccines have seen their stocks skyrocket, and one such company is Ibio Inc (NYSEAMERICAN:IBIO). is working to develop a collagen derivative, IBIO-100, that could be dosed orally to treat life-threatening fibrotic diseases. Quotes & Research Flash Quotes InfoQuotes Summary Quotes Real-time Quotes Extended Trading. Looking at the stock we see that its previous close was $1. 52, while invested capital returns managed to touch -51. is a biotechnology company. He brings extensive finance transformation, strategic development and partnership, internal control and regulatory compliance background to iBio, Inc. The additions will be made effective after the U. The Company is focused on the d evelopment and commercialization of novel plant-made products for the prevention and treatment of serious. He consults for pharma and bio-pharma companies in biologic therapeutics. • List of IBIO Customers. Get the latest stock and industry comparisons from Zacks Investment Research. Thinking about buying stock in Edesa Biotech, iBio Inc, Pfizer Inc, Lexicon Pharmaceuticals, or Apache Corp? Thinking about buying stock in Moderna, Ocugen Inc, Advanced Micro Devices, iBio Inc, or Taiwan Semiconductor? Thinking about buying stock in Zomedica Pharmaceuticals, iBio Inc, Achieve Life Sciences, Intec Pharma, or Apple Inc?. In another most recent transaction, which held on 6/30/2020, WEDBUSH SECURITIES, INC. 3 weeks IBIO Stock Price: iBioPharma Inc to attract Robinhood bargain-seekers amid doubtful Russia’s vaccine FXStreet. 07% on Tuesday amidst FDA backtracking on plasma treatments for COVID-19. gains, shrugging off pullback for biotech plasma players FXStreet. Big Pharma won't like Trump's next move after rebate rule is abandoned, investors fear. FASTPHARMING® trademark registration is intended to cover the categories of pharmaceutical. (NYSE: IBIO) was a big gainer in yesterday’s trading session. Robbins Arroyo LLP: iBio, Inc. Apr 7, 2014 11:12 AM EDT. 13, after gaining 5. Its main area of business is plant-based protein expression technologies for vaccines and therapeutic proteins and developing and commercializing select biopharmaceutical. iBio is developing proprietary products for the treatment of a range of fibrotic diseases including idiopathic pulmonary fibrosis, systemic sclerosis, and scleroderma. iBioPharma Inc is working on a plant-based COVID-19 vaccine with Beijing CC-Pharming Ltd. Environment 43 Employees 50 Community 43 Governance 56. Horizon Therapeutics, Astellas Pharma US and Baxter International Inc. NYSEAMERICAN:IBIO has developed a substantial cult following in penny stock circles as bargain-hunting investors continue to back iBio as a potential. (IBIO Stock Report) was one of the early winners when it came to the coronavirus. (NYSE: IBIO) was a big gainer in yesterday’s trading session. iBio, a leader in developing plant-based biopharmaceuticals, provides a range of product and process development, analytical, and manufacturing services at the large-scale development and manufacturing facility of its subsidiary iBio CDMO, LLC in Bryan, Texas. Pharmaceutical company iBio Inc. iBio, Inc introduced new cGMP sterile fill-finish capabilities for pharmaceutical products, including monoclonal antibodies, viral vectors, and other biologics. is working to develop a collagen derivative, IBIO-100, that could be dosed orally to treat life-threatening fibrotic diseases. Lets take a look at what they do as a company: “iBio is an innovator biologics company developing therapeutics and vaccines […]. invenious ™ aims to make the delivery of infusible medicines more effective, safer and simpler, while increasing value to patients, providers and payers. describes itself as an innovative biological company developing therapies and vaccines for human and animal welfare, including a virus-like particle (VLP) vaccine. Robbins Arroyo LLP: iBio, Inc. During the day, the stock rose to $4. Thinking about buying stock in Zomedica Pharmaceuticals, iBio Inc, Achieve Life Sciences, Intec Pharma, or Apple Inc? Provided by PR Newswire Jul 22, 2020 2:35 PM UTC Sponsor Center. 0027 [email protected] About iBio, Inc. In early February, the company announced a partnership with China-based CC-Pharming to develop a vaccine for the coronavirus. 001 PAR VALUE PER SHARE (Title of Class of Securities) 451033203 (CUSIP Number) William Sullivan, 10. As it relates to biotech companies, there are a number of factors that have the ability to cause gains in the market. "iBio Inc is a part of the healthcare sector. The micro-cap biotech company remains a penny-stock darling despite having only a longshot for. The net margin for iBio, Inc. August 31 - Muslim Farooque - "Ibio Is an Afterthought in the Covid-19 Vaccine Race" September 1 - Faizan Farooque - "Ibio's Time Is Running Out in Vaccine Chase" September 2 - Lou Carlozo - "At This Point, iBioPharma Is a Flash in the Pandemic" Interesting that all of them have iBio so strongly on their minds at the same time. , a biotechnology innovator and biologics contract manufacturing organization, has entered into an exclusive worldwide license agreement with Planet Biotechnology Inc. (NYSE AMERICAN:IBIO) today announced that it has expanded the scope of its business venture with CC-Pharming Ltd. The COVID-19 pandemic is an extraordinary global public health crisis. - August 24, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities who purchased Cancer Genetics, Inc. Kitov Pharma | 513 followers on LinkedIn | We are a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, to create successful long-lasting treatments for people with cancer. This came after it announced that, it working jointly with CC-Pharming Ltd to develop a vaccine for Coronavirus. for the development of Planet's COVID-19 therapeutic candidate, ACE2-Fc. , its former neighbor in the Delaware Technology Park. Its main area of business is plant-based protein expression technologies for vaccines and therapeutic proteins and developing and commercializing select biopharmaceutical. Enabling Next - Gen Biologics Offering Summary 4 Issuer iBio, Inc. 71% on April 27. The statement about iBio collecting pre-clinical data on IBIO-201 wouldn’t be bad news under normal circumstances, but the fight against Covid-19 isn’t normal. iBIO Fellows. , and BioCryst Pharmaceuticals, Inc. Wainwright published a research note on March 05, 2019 where it informed investors and clients that Evoke Pharma Inc. SG AMERICAS SECURITIES LLC bought a fresh place in iBio Inc. Contract Pharma | 2,299 obserwujących | From drug development to manufacturing, we cover the latest developments, views & opinions from the pharma industry | CONTRACT PHARMA is the multi media information outlet dedicated to bio/pharma outsourcing. is a pharmaceutical company, which engages in the contract development and manufacturing organization (CDMO). IBio is now headquartered in New York City. 55; List of ETFs holding TRIL; 4) Nautilus Group, Inc. , formerly known as iBioPharma Inc. To see if your Company qualifies for coverage, call 310-594-8062 Contact us: [email protected] He brings extensive finance transformation, strategic development and partnership, internal control and regulatory compliance background to iBio, Inc. It operates through the iBio, Inc. View Walt Johnston's business profile as Urology & Hospital Senior VP, Sales & Marketing at iBIO Institute. (NYSE MKT: IBIO), a leader in the plant-made pharmaceutical field, develops and offers pharmaceutical product applications using its iBio Technology platform. 91; List of ETFs holding NLS; 5) iBio. can be a profitable investment option. The stock, one that is focused in the biotechnology sector, is presently priced at $0. 07% on Tuesday amidst FDA backtracking on plasma treatments for COVID-19. iBio CDMO, LLC 8800 HSC Pkwy Bryan, TX 77807. VERIFIED Status: UNVERIFIED. has a license to market LO2A - a drug in the field of Dry Eye, with additional indications as CCh and Sjogren Syndrom. The statement about iBio collecting pre-clinical data on IBIO-201 wouldn’t be bad news under normal circumstances, but the fight against Covid-19 isn’t normal. Focused initially on clients with preclinical and clinical stage programs, iBio’s fill-finish operation is housed in the Company’s 135,000 square foot CDMO facility. Taking a look at stock we notice that its last check on previous day was $4. Current estimates show this company has an annual revenue of 2018000 and employs a staff of approximately 43. A bio-pharmaceutical company focused on the development and commercialization of novel plant-made products for the prevention and treatment of serious infectious diseases. 30 in pre-market trading today on no news. : iBio, Inc. iBio is investigating an array of adjuvants in combination with iBio's proprietary. Market capitalization usually refers to the total value of a company's stock within the entire market. 3) Trillium Therapeutics Inc. 2%) & daily performaces for comparison. iBio has had a steady advance during the COVID-19 spreading worldwide. , a biotechnology innovator and biologics contract manufacturing organization, has entered into an exclusive worldwide license agreement with Planet Biotechnology Inc. iBio’s unique plant-based platform has garnered significant interest from manufacturers, scientists, and the public, primarily due to its. 83% 2020 year-to-date; Market Capitalization: $877. The link explaining its purchase can be found here. Clover Biopharmaceuticals, Heat Biologics Inc. Currencies (Forex) · Stocks. for the development of Planet's COVID-19 therapeutic candidate, ACE2-Fc. Exchange / Ticker NYSE American: IBIO Offering Size Up to $15M (100% Secondary) Over Allotment 15% (100% Secondary) Offering Details Common Stock, Preferred Stock and Warrants Use of Proceeds We intend to use the net proceeds from this offering for working capital and general corporate purposes Sole Book - Runner A. , a biotechnology company, provides product development and manufacturing services to clients, collaborators, and third-party customers in the United States and internationally. iBio CMO engaged McDAY to increase awareness of their plant-made pharmaceutical (PMP) technology platform. (AIKI) Ownership Facts and Figures. (IBIO) stock discussion in Yahoo Finance's forum. Its FastPharming System™ combines vertical farming, automated hydroponics, and glycan engineering technologies to rapidly deliver gram quantities of high-quality monoclonal antibodies, vaccines, bioinks and other proteins. Thinking about buying stock in Zomedica Pharmaceuticals, iBio Inc, Achieve Life Sciences, Intec Pharma, or Apple Inc? Provided by PR Newswire Jul 22, 2020 2:35 PM UTC Sponsor Center. From being too expensive to becoming too cheap? That could be the thinking behind the pre-market price rise that NYSEAMERICAN: IBIO is experiencing on. is a revenue-generating, specialty pharmaceutical company focused on providing innovative, high-quality brands that meet the needs of acute care physicians and patients. About iBio, Inc. (AMEX:IBIO). AIkido Pharma Inc. Meanwhile, IBIO-201 and IBIO-200 are still at the pre-clinical stage. 07% on Tuesday amidst FDA backtracking on plasma treatments for COVID-19. 2019-03-15 sec. gains, shrugging off pullback for biotech plasma players FXStreet. The next entry in the theme of Corona Virus stocks is iBioPharma Inc. NYSEAMERICAN:IBIO gained 4. ”157 Sections 1. since April 1, 2019 and also served as Co-Chairman at iBio, Inc. DUNS 010634930. iBio’s subsidiary, iBio CDMO is a global leader in plant-based manufacturing. Shares of iBio have skyrocketed more. tradingview. The statement about iBio collecting pre-clinical data on IBIO-201 wouldn’t be bad news under normal circumstances, but the fight against Covid-19 isn’t normal. Time is, unfortunately, not on iBio’s side as the race for the vaccine is already progressing at a rapid pace. Chris Markoch at Investor Place called readers to "stay away. The Texas A&M University System (TAMUS), including Texas A & M University AgriLife Research, and the Texas A&M Institute of Infectious Animal Diseases (IIAD), has executed a joint development agreement with iBio, Inc. 26 2010, IBIO announced that it has agreed in principle to license its technology, the iBioLaunch™ platform, and provide technology transfer services to G-Con, LLC, a private Texas company, and its affiliates, for the development and manufacture of plant-expressed influenza vaccines at a new facility being constructed in Bryan, Texas. Chris Markoch at Investor Place called readers to "stay away. The deal, also includes iBio granting a license to caliber to make use of the company’s patented products for drug development. 29% 2020 year-to-date; Market Capitalization: $468. Cocrystal Pharma, Inc. tradingview. iBio is a technology platform that develops pharmaceutical product applications. ’s current insider ownership accounts for 5. : iBio, Inc. However, these declines my prove to be a discounted opportunity to get in on potentially strong gains ahead. 1,271 likes · 43 talking about this. (IBIO) obtained an estimated Buy proposal from the 1 brokerage firms currently keeping a deep eye on the stock performance as compares to its rivals. 26, 2019 (GLOBE NEWSWIRE) -- iBio, Inc. Price Gain: 794. Share your opinion and gain insight from other stock traders and investors. iBio Pharma (NYSEMKT:IBIO) and Vaxart (NASDAQ:VXRT) rank as two of the biggest winners so far this year among small-cap biotechs with coronavirus programs. Report Highlights: • The Angioedema Treatment report provides a detailed analysis of current and future Angioedema Treatment market trends to identify investment. The micro-cap biotech company remains a penny-stock darling despite having only a longshot for. 0 equity research analysts rated the shares with a selling strategy, 0 gave a hold approach, 1 gave a purchase tip, 0 gave the firm a overweight advice and 0 put the stock under the underweight category. Current estimates show this company has an annual revenue of 2018000 and employs a staff of approximately 43. IBIO / iBio Inc. (AMEX:IBIO). (NYSE MKT: IBIO), a leader in the plant-made pharmaceutical field, develops and offers pharmaceutical product applications using its iBio Technology platform. Its main area of business is plant-based protein expression technologies for vaccines and therapeutic proteins and developing and commercializing select biopharmaceutical. He consults for pharma and bio-pharma companies in biologic therapeutics. ($ IBIO) is gaining a lot of interest from analysts and stock traders this week. , and its subsidiary, iBio CMO LLC in Bryan/College Station, Texas for the establishment of a collaborative program in plant-produced pharmaceuticals. 07% on Tuesday amidst FDA backtracking on plasma treatments for COVID-19. Eastern Capital then revealed in a separate filing that it sold an. (NYSEAMERICAN:IBIO) has announced that it has been selected by IBM Watson Health to use the IBM Clinical Development solution for 18 months. 600 Madison Avenue Suite 1601 New York, NY 10022. As it relates to biotech companies, there are a number of factors that have the ability to cause gains in the market. Reddit gives you the best of the internet in one place. The Company is focused on commercializing its technologies and product candidates and providing product development and manufacturing services to clients and collaborators. The blue-chip FTSE 100was down 0. The split for IBIO took place on June 11, 2018. – IBIO-201 Demonstrates Ability to Elicit anti-SARS-CoV-2 Immune Response in Preclinical Studies – NEW YORK, Aug. According to WSJ, iBio Inc. NEW YORK, Dec. Find contact's direct phone number, email address, work history, and more. , is a global leader in plant-based biologics manufacturing. iBio Inc iBio, Inc. The company currently falls under 'Small-Cap' category with current market capitalization of 343. NYSEAMERICAN: IBIO is benefiting from impressive performance amid an ever-crowding field of pharma firms racing. , a biologics CMO and biotechnology company, is working to develop vaccine candidates to prevent infection from the SARS-CoV-2 virus that causes COVID-19 disease. iBio has had a steady advance during the COVID-19 spreading worldwide. 91; List of ETFs holding NLS; 5) iBio. Stock Downgraded (ATRS) By Kevin Baker. He also held the position of CEO of H Lundbeck A/S, a pharmaceutical company specialized in psychiatric and neurological disorders, for several years. Senior management and leadership work diligently to ensure that employees feel valued and provide opportunities to grow professionally. The net margin for iBio, Inc. It operates through the iBio, Inc. - Licenses to iBio's Bio-Better Rituximab and FastPharming™ System Expand Commercial Partnership - NEW YORK, Aug. Berkeley Lovelace Jr. ($ IBIO) is gaining a lot of interest from analysts and stock traders this week.